NCT02447419已完成2 期
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- overall response rate
研究概览
简要总结
This study is a single-arm,phase II study of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors.
Gefitinib 250 mg will be administered orally daily.
To investigate the efficacy and safety of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of fully informed consent prior to any study specific procedures.
- •Patients must be ≥20 years of age.
- •Patient with Epidermal growth factor receptor amplification Refractory Solid Tumors and/or specific sensitivity to Gefitinib by Avatar scan that has recurred or progressed following standard therapy, or that has not responded to standard therapy, or for which there is no standard therapy.
- •(EGFR amplification by cancer scan + EGFR IHC overexpression +2 or +3)
- •ECOG performance status 0-
- •Have measurable or evaluated disease based on RECIST1.
- •as determined by investigator.
- •Adequate Organ Function Laboratory Values
- •Absolute neutrophil count ≥ 1.5 x 109/L, Hemoglobin ≥ 9g/dL, Platelets ≥ 100 x 109/L
- •bilirubin ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal (5.0 X upper limit of normal , for subjects with liver metastases)
- •creatinine ≤1.5 x UNL
- •Patients of child-bearing potential should be using adequate contraceptive measures (two forms of highly reliable methods) should not be breast feeding and must have a negative pregnancy test prior to start of dosing.
- •Adequate heart function.
排除标准
- •Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
- •Has known active central nervous system (CNS) metastases.
- •Has an active infection requiring systemic therapy.
- •Pregnancy or breast feeding
- •Patients with cardiac problem.
- •KRAS mutation (codon 12 or 13) or BRAF mutation (V600)
- •Any previous treatment with Gefitinib
- •Patients with a risk factor of interstitial lung disease
研究组 & 干预措施
Gefitinib
Experimental
Gefitinib 250 mg will be administered orally daily
干预措施: Gefitinib (Drug)
结局指标
主要结局
overall response rate
时间窗: up too 100 weeks
次要结局
- progression-free survival(expected average of 24 weeks)
- Number of subjects with Adverse Events as a measure of safety(up too 100 weeks)
- overall survival(up too 100 weeks)
研究者
Jeeyun Lee
MD,PhD
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
暂停
2 期
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT00986284Tianjin Medical University Cancer Institute and Hospital102
Unknown
2 期
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)Nonsmall Cell Lung CancerNCT01312337Samsung Medical Center92
已完成
2 期
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryNon-small Cell Lung CancerNCT02804776National Cancer Centre, Singapore15
已完成
3 期
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneNon-Small Cell Lung CancerNCT01544179AstraZeneca265
已完成
1 期
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaNCT00052208National Cancer Institute (NCI)158